DVA.V - Delivra Corp.

TSXV - TSXV Delayed Price. Currency in CAD
0.40
+0.00 (+1.27%)
At close: 11:33AM EST
Stock chart is not supported by your current browser
Previous Close0.40
Open0.40
Bid0.40 x 0
Ask0.40 x 0
Day's Range0.40 - 0.40
52 Week Range0.33 - 0.59
Volume7,000
Avg. Volume122,918
Market Cap17.559M
Beta-2.94
PE Ratio (TTM)N/A
EPS (TTM)-0.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE10 days ago

    Canadian Exchanges Stock Scanner Maple Leaf Green World GreenSpace Brands Naturally Splendid Enterprises and Delivra

    LONDON, UK / ACCESSWIRE / February 15, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Consumer-Packaged Goods industry: Maple Leaf Green ...

  • CNW Group24 days ago

    Delivra Signs Distribution Agreement With NKS Health for Ready to Market Compounded Finished Products to Medical Doctors

    TORONTO, Feb. 1, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") announced today that it has signed a non-exclusive distribution agreement with NKS Health Ltd. ("NKS"), granting NKS the right to compound, distribute, promote, market and sell new unique pharmaceutical compounded product formulas developed by Delivra. The goal of the agreement is to build a partnership to both grow awareness and increase volume of sales for the Company's pharmaceutical pipeline. NKS will promote Delivra's cream-base therapeutics to physicians, hospitals and clinics in Canada through its network.  Delivra has developed a suite of compounded products for pain, anxiety and diabetic foot ulcers.

  • Baystreetlast month

    Stocks in play: Delivra Corp

    Has signed a joint venture agreement using Delivra's revolutionary, proprietary topical therapeutic ...

  • CNW Grouplast month

    Delivra develops a revolutionary topical cream utilizing cannabis and opioid molecules for safer delivery in patients with chronic pain and anxiety

    TORONTO, Jan. 16, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") announced today the Company has developed a revolutionary, proprietary topical cream base therapeutic, DelivraTMN, for molecules of Cannabis, Cannabis-like and opioids, for a safer, more targeted and consistent delivery to patients afflicted with chronic pain and anxiety. "Our goal is to develop innovative products using our proprietary topical delivery platform (DelivraTM) to meet significant unmet medical needs and improve quality of life. With our proven patent-pending technology and formulation expertise, we have created medical grade products that have shown significant efficacy and predictable outcomes to patients," said Dr. Joseph Gabriele, CEO of Delivra.

  • ACCESSWIRElast month

    Canadian Exchanges Stock Scanner, Maple Leaf Green World, GreenSpace Brands, Naturally Splendid Enterprises, and Delivra

    LONDON, UK / ACCESSWIRE / January 12, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Consumer Packaged Goods industry: Maple Leaf Green World, ...

  • Marketwired3 months ago

    Delivra Announces Record Sales Growth for the Quarter

    Delivra Corp. reported its financial results for the three and nine months ended September 30, 2017. All figures are reported in CDN dollars , unless otherwise indicated. Delivra's financial...

  • Marketwired5 months ago

    Delivra Appoints Chief Marketing Officer

    Delivra Corp. , announced today the appointment of Howard Lichtman to the position of Chief Marketing Officer . "Howard is a highly-experienced, accomplished business leader with a proven track......